Biogel Kit Using Non-Covalent Fibrinogen Binding

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current tissue adhesives, such as fibrin tissue adhesives, often use toxic agents like bovine thrombin, which can induce anaphylactic and autoimmune responses, and are complex to produce, requiring specialized formulations and storage conditions.

Innovation Solution

A biogel kit comprising soluble carriers with immobilized fibrinogen binding moieties or precursors that form non-covalent bonds with fibrinogen, allowing for the creation of a biogel or tissue adhesive without the need for toxic agents, simplifying production and storage.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If bovine thrombin is used in fibrin tissue adhesive, then the tissue adhesive can form a stable gel, but it induces anaphylactic and autoimmune responses in patients

Engineering Contradiction:
Improvegel stabilityVSAvoidanaphylactic and autoimmune responses
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention extracts and removes the harmful bovine thrombin component from the fibrin tissue adhesive formulation, replacing it with alternative agents that do not induce anaphylactic or autoimmune responses, while maintaining the gel-forming capability through other mechanisms

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention introduces alternative thrombin substitutes or activators as intermediary substances that can perform the necessary fibrinogen-to-fibrin conversion without the harmful immunogenic properties of bovine thrombin, serving as a safe mediator in the gel formation process

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If specialized formulations and storage conditions are used for current tissue adhesives, then the tissue adhesive can be effective, but the production and storage become complex

Engineering Contradiction:
Improvetissue adhesive effectivenessVSAvoidproduction and storage complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The invention employs stable, non-enzymatic alternative agents that do not require specialized storage conditions (such as refrigeration or controlled environments), allowing for simpler, more robust formulations that can be stored and handled under standard conditions, effectively replacing the need for complex storage infrastructure

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The invention changes the fundamental parameters of the formulation by using alternative chemical or physical mechanisms instead of enzymatic reactions, which eliminates the need for temperature-controlled storage and simplifies the overall production and storage requirements while maintaining effectiveness

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The biogel kit provides a safe, easy-to-produce tissue adhesive that minimizes allergic reactions and toxic exposure, with the ability to form a stable gel for applications like haemostasis, drug delivery, and tissue engineering, without requiring thrombin or other enzymes.

Implementation Method 1

Non-covalent bonds are formed between the fibrinogen molecules and the fibrinogen binding moieties

Methodology Applied
Scientific EffectNon-covalent bonding: Van der Waals Force

Data Source

PatentEP3095468B1biogel
Publication Date: 2021.08.11 HAEMOSTATIX LTD
  • EP3095468B1 patent drawingFigure 1(a)~1(c)
  • EP3095468B1 patent drawingFigure 2(A)~2(B)
  • EP3095468B1 patent drawingFigure 3

AI summary

A biogel, and kits, agents, and methods for formation of the biogel are described. The biogel can be used for a variety of applications, including haemostasis, wound sealing, tissue engineering or localised drug delivery.